Proteostasis files $86M IPO; Novartis publishes Cosentyx studies;

> Cambridge, MA-based Proteostasis Therapeutcs filed for an $86 million IPO. Filing

> Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis's Cosentyx (secukinumab) in ankylosing spondylitis were published in The New England Journal of Medicine. Release